IMNM - CIK 0001472012
Immunome Inc. (IMNM) reported net income of -$212.39M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$212.39M | +27.5% |
| FY 2024 | -$292.96M | -174.3% |
| FY 2023 | -$106.81M | -189.5% |
| FY 2022 | -$36.90M | -49.3% |
| FY 2021 | -$24.71M | -38.5% |
| FY 2020 | -$17.84M | -70.8% |
| FY 2019 | -$10.44M | - |
Immunome Inc. (IMNM) reported net income of -$212.39M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, Immunome Inc.'s net income declined from -$10.44M to -$212.39M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.